As of November 7, 2026, CG Oncology, Inc. is a publicly traded company (Nasdaq: CGON). The largest holder reporting an active stake on Schedule 13D is Longitude Capital Partners IV, LLC, at 6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include RTW Investments (9.7%), T. Rowe Price (8%), BlackRock (6.8%) (Schedule 13D, September 18, 2025).
Is this your company?
About to sign with, pay or invest in CG Oncology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is CG Oncology, Inc. a real, registered company?
- CG Oncology, Inc. files with the SEC under CIK 1991792 (its SEC filings).
- Its shares are listed under the ticker CGON on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Dallas, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CG Oncology, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RTW Investments (filed 2026-08-14).
Who are CG Oncology, Inc.'s owners and officers?
CG Oncology, Inc.: incorporated in Delaware; business address in Dallas, Texas; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | James B. Tananbaum | 4.9% |
| Schedule 13G/A, 2026-08-14 | Rtw Investments, LP | 9.7% |
| Schedule 13G/A, 2026-08-13 | Wellington Management Group LLP | 6% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 6.8% |
| Schedule 13G, 2026-05-15 | Rtw Investments, LP | 8.3% |
| Schedule 13G, 2026-05-15 | T. Rowe Price Investment Management, Inc. | 8% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G, 2025-11-12 | Wellington Management Group LLP | 7.2% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 8.62% |
| Schedule 13D/A, 2025-10-28 | Seven Fleet Capital Management LP | 2% |
| Schedule 13D, 2025-09-18 | Longitude Capital Partners Iv, LLC | 6% |
| Schedule 13D, 2025-09-18 | Seven Fleet Partners LP | 2% |
Questions about who owns CG Oncology, Inc.
Who owns CG Oncology, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of CG Oncology, Inc.: Rtw Investments, LP (9.7%, Schedule 13G/A, filed 2026-08-14), T. Rowe Price Investment Management, Inc. (8%, Schedule 13G, filed 2026-05-15), Blackrock, Inc. (6.8%, Schedule 13G/A, filed 2026-07-27), Wellington Management Group LLP (6%, Schedule 13G/A, filed 2026-08-13) and Longitude Capital Partners Iv, LLC (6%, Schedule 13D, filed 2025-09-18).
Who are the largest shareholders of CG Oncology, Inc.?
By the share each holder's latest filing reports, the largest holders of CG Oncology, Inc. on this page are Rtw Investments, LP (9.7%), T. Rowe Price Investment Management, Inc. (8%) and Blackrock, Inc. (6.8%).
When did Rtw Investments, LP buy into CG Oncology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Rtw Investments, LP on this page is the Schedule 13G, filed 2026-05-15, reporting 8.3%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on CG Oncology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CG Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CG Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own CG Oncology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 7,039,077 shares (7.9% of shares outstanding), 613,928 held directly and 6,425,149 indirectly (Form 4, 2025-09-04).
- , a director: 1,886,236 shares (2.1% of shares outstanding), held indirectly through By Seven Fleet Partners LP (Form 4, 2026-06-29).
- , the chief executive and a director: 198,916 shares (0.22% of shares outstanding) (Form 4, 2026-03-13).
Shares outstanding: 89,318,916 as of 2026-11-04, from the company's latest SEC cover page.
How much has CG Oncology, Inc. raised?
Latest IPO step: CG Oncology, Inc. filed its final IPO prospectus (424B4, 2024-12-13).
IPO filings: 424B4, 2024-12-13, S-1/A, 2024-12-11, S-1, 2024-12-11.
Keep reading
More on CG Oncology, Inc. and the records around it.
CG Oncology, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: Lexeo Therapeutics, Inc. (Nov 2025), ZENAS BIOPHARMA, INC. (Oct 2025)
- Seven Fleet Master Fund LP also filed stake reports on 3 other companies: Entera Bio, Ltd. (the "Issuer") (Aug 2026), CytomX Therapeutics, Inc. (May 2026), Veradermics, Inc (May 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026), ORUKA THERAPEUTICS, INC. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cg-oncology